INTRODUCTION
Changes in circulating glucose modulate insulin production by the b cells of the pancreatic islets of Langerhans. In turn, insulin influences glucose uptake in insulin-sensitive peripheral tissues such as fat and muscle, and maintains glucose homeostasis (Rhodes and White, 2002) . As a key metabolic factor, insulin levels are tightly regulated by different mechanisms. Insulin is produced by proteolytic cleavage of preproinsulin in pancreatic b cells. Preproinsulin is encoded by insulin mRNA, a highly abundant transcript in b cells (>30% of total mRNA) with an exceptionally long half-life (>24 hr) due to the presence of a pyrimidine-rich stretch in its 3 0 untranslated region (UTR) (Itoh and Okamoto, 1980; Goodge and Hutton, 2000) . Tillmar and Welsh (2002) identified the RNA-binding protein (RBP) polypyrimidine tract-binding protein (PTB) as being responsible for associating with the pyrimidine-rich stretch in insulin mRNA and contributing to its high stability. Increased glucose availability enhanced PTB binding to insulin mRNA and elevated its levels; hours later, insulin mRNA was also transcriptionally upregulated (Jahr et al., 1980) . However, in response to acute elevations in circulating glucose, the necessary and timely rise in insulin production is primarily controlled by rapid increases in the translation of insulin mRNA in b cells. Wicksteed and coworkers (2001) reported that insulin translation was regulated through the cooperative action of a stem loop in the 5 0 UTR and the conserved UUGAA sequence in the 3 0 UTR. A 9 nt element present in the insulin 5 0 UTR was shown to be responsible for the glucose-dependent translational increase in insulin production (Wicksteed et al., 2007) . A 29 nt long element within the rat insulin 5 0 UTR was also found to contribute to the glucose-triggered translational upregulation (Muralidharan et al., 2007) . However, the specific factor(s) that associate with these elements were unknown.
Here, we identify HuD (human antigen D) as an RBP that binds to insulin mRNA and controls its translation. Like two other Hu family members (HuB and HuC), HuD was believed to be expressed specifically in neurons, while the remaining member, HuR was ubiquitous (Hinman and Lou, 2008) . However, a recent survey of HuD expression in different tissues (Abdelmohsen et al., 2010) , unexpectedly revealed HuD expression in pancreatic b cells. Hu proteins have three RNA recognition motifs (RRMs) through which they associate with mRNAs bearing specific sequences that are often AU-and U-rich. HuD bound to the 3 0 UTR of target mRNAs and stabilized them, as shown for p21, tau and GAP-43 mRNAs (for review, see Hinman and Lou, 2008) . HuD also modulated target mRNA translation; for (C-E) Western blot analyses of the levels of HuD, IR b subunit (IRb), and loading control b-actin in bIRWT and bIRKO cells cultured for 16 hr in 2 mM glucose, and further cultured for 6 hr with the indicated glucose concentrations (C), in bIRKO cells transfected with either an control plasmid (vector) or with a plasmid that expressed IR (D), and in bIRWT cells cultured in 2 mM glucose + 0.1% FBS for 24 hr before insulin treatment for the indicated times (E).
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HuD Represses Insulin Translation example, interaction of HuD with the p27 mRNA disrupted an internal ribosome entry site (IRES) and inhibited p27 translation (Kullmann et al., 2002) , whereas HuD enhanced the stability and translation of Nova1 mRNA (Ratti et al., 2008) . Despite the short and unstructured 5 0 UTRs of the human insulin (INS) mRNA and the mouse ortholog (Ins2 mRNA), HuD binding to the Ins2 5 0 UTR repressed Ins2 mRNA translation and decreased insulin production. Accordingly, HuD knockout mice expressed higher levels of insulin in b cells, whereas HuD-overexpressing mice expressed lower insulin levels in b cells and in the circulation.
RESULTS

HuD Is Expressed in Pancreatic b Cells
Immunostaining of human and mouse pancreatic sections detected HuD in insulin-producing, b cells ( Figure 1A) ; HuD was also expressed in brain, but not in other mouse tissues (Figure 1B; Figures S1A and S1C available online) . By western blot analysis, HuD levels in immortalized b cells isolated from the pancreas of wild-type (bIRWT) mice were significantly higher and more glucose-inducible than those in b cells isolated from an insulin receptor (IR) null (bIRKO) mouse ( Figure 1C ; Assmann et al., 2009; Kim et al., 2011) ; ectopic IR re-expression in bIRKO cells restored HuD abundance under conditions of low glucose and low serum ( Figure 1D ). Treatment of bIRWT cells with insulin similarly elevated HuD levels in a dose-dependent manner (Figure 1E) . In mouse insulinoma bTC6 cells, silencing the insulin receptor substrate 2 (Irs2), a downstream effector of IR signaling, lowered HuD levels ( Figure 1F ). Likewise, silencing or inhibiting Akt, a kinase that functions downstream of Irs2, also lowered HuD levels ( Figures 1G and 1H ), as did inhibiting the Akt kinase PI3K using LY294002 ( Figure 1H ). Akt phosphorylates and thereby inactivates the transcriptional repressor FoxO1; in keeping with the putative FoxO1 binding site in the HuD promoter (492 bp from the transcription start site), chromatin immunoprecipitation (ChIP) analysis in bTC6 cells revealed an interaction of FoxO1 with the HuD promoter. FoxO1 showed greater association with the HuD promoter in conditions of low glucose and reduced association in high glucose ( Figure 1I ; Figure S1B) . As shown, silencing FoxO1 in bIRWT and bTC6 cells augmented HuD expression levels ( Figures 1J and 1K) . Conversely, overexpression of FoxO1 reduced HuD production, while overexpression of the transcription-deficient Fox-O1(H215R-537), bearing a mutation in the DNA binding domain (H215R) and C-terminal deletion in the transactivation domain (Zhang et al., 2011) did not ( Figure 1L ). Together, these data indicate that HuD is expressed in b cells under control of the pathway IR / Irs2 / PI3K / Akt C FoxO1 (/) HuD ( Figure 1M ). (Figure 2A) . To map the RNA region of association, biotinylated segments spanning the 5 0 UTR, CR, and 3 0 UTR of Ins2 mRNA were synthesized ( Figure 2B ), and the RNP complexes of HuD and biotinylated RNAs was detected by biotin pull-down analysis using streptavidin-coated beads. As shown in Figure 2C (A) HuD interaction with Ins2 mRNA was studied by RIP analysis using anti-HuD or control IgG antibodies. RNA was isolated, and Ins2 mRNA levels measured by reverse transcription-quantitative PCR analysis (RT-qPCR) and normalized to Gapdh mRNA levels.
HuD Binds to
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HuD Represses Insulin Translation Likewise, endogenous Ins2 mRNA levels in bTC6 cells did not change after silencing HuD, while expression of the encoded insulin precursor (proinsulin) increased markedly ( Figure 2H versus 2I) without changes in proinsulin protein stability (Figure S2C ). These data indicate that HuD associates with the Ins2 mRNA 5 0 UTR, and that this interaction represses insulin production, likely by inhibiting its translation.
More direct evidence that HuD represses translation of the Ins2 mRNA was obtained by polysome analysis in bTC6 cells expressing different HuD levels. Cytoplasmic extracts from control and HuD-silenced cells were fractionated through sucrose gradients, with the lightest components sedimenting at the top (fractions 1 and 2), small (40S) and large (60S) ribosomal subunits and monosomes (80S) in fractions 3-5, and progressively larger polysomes, ranging from low-to high-molecular-weight (LMWP, HMWP) in fractions 6-12 ( Figure 2J , left). While in Ctrl siRNA cells, polysome-associated Ins2 mRNA peaked in fractions 6 and 7, silencing HuD increased the peak size of Ins2 mRNA polysomes to fraction 8 ( Figure 2J , right). The distribution of the housekeeping Actin mRNA largely overlapped between the two groups ( Figure 2J , right). Additional evidence that HuD modulated insulin translation was gained from nascent translation analysis. The incorporation of 35 S-Met and 35 S-Cys into newly synthesized proinsulin during a brief time period (15 min), immediately followed by IP using anti-insulin antibody, showed enhanced translation of proinsulin in the HuD siRNA group, whereas translation of the housekeeping protein GAPDH was unchanged between the two groups ( Figure 2K ; signals were characteristically faint, reflecting the short labeling time). Together, these findings strongly indicate that HuD represses Ins2 production by reducing Ins2 mRNA translation.
HuD-Ins2 mRNA RNP Complexes Reduced after Glucose Stimulation
Analysis of HuD-Ins2 mRNA complexes in bTC6 cells revealed a rapid and robust release of Ins2 mRNA from HuD complex within 30 min of glucose stimulation (25 mM glucose; Figure 3A ). In keeping with the view that HuD represses insulin production, glucose treatment (15 mM, 20 min) elevated proinsulin abundance in control cells (vector), but this increase was largely lost in cells overexpressing HuD (Figure 3B , left; Figure S3A ). These changes occurred without changes in Ins2 mRNA levels (Figure 3B , right) but were accompanied by changes in nascent translation of proinsulin ( Figure 3C ). Conversely, glucose treatment (15 mM, 20 min) elevated proinsulin abundance in cells transfected with Ctrl siRNA, while HuD-silenced cells expressed significantly higher levels of proinsulin, as assessed by western blotting ( Figure 3D ) and by ELISA measurement of intracellular and secreted insulin ( Figure 3E ). Again, changes in proinsulin and insulin production occurred without changes in Ins2 mRNA levels ( Figure 3D , graph). Similar trends were observed for C-peptide (a linker between the A and B chains of insulin) in bTC6 cells ( Figure 3F ) and for insulin and Ins2 mRNA measured in other pancreatic b cells ( Figures S3B and S3C ). The influence of HuD on insulin expression was further studied by immunofluorescence. HuD subcellular distribution was visualized relative to the distribution of two subcellular RNA granules associated with gene repression, processing bodies (PBs), detected using an antibody that recognizes the decapping protein Dcp1, and stress granules (SGs), detected using an antibody that recognizes TIAR. As shown in Figure 3G , HuD was abundant in the cytoplasm of bTC6 cells, in keeping with its distribution in neurons. In untreated cells, PBs were readily visible while no SGs were detected; interestingly, by 15 and 30 min after glucose stimulation, HuD colocalized in part with cellular PBs and with a few visible SGs ( Figure 3G ; Figures S3D and S3E ).
Insulin Levels in HuD Knockout and Transgenic Mice
Mice bearing with deletions in both HuD alleles (HuDÀ/À) or one HuD allele (HuD+/À) showed impaired neuronal differentiation (Pascale et al., 2004; Akamatsu et al., 2005) , in keeping with the neuronal presence of HuD. Analysis of pancreas from these mice revealed that insulin levels were highest in pancreatic b cells from HuDÀ/À mice, moderately lower in HuD+/À mice, and lowest in HuD+/+ mice, as assessed by immunofluorescence ( Figure 4A ), and by western blot and ELISA analysis of insulin production (Figures 4B-4E ; Figure S4A ). Thus, in HuDÀ/À mice, the absence of HuD contributed to elevating constitutive insulin and proinsulin levels in b cells.
To further test the possibility that HuD controls insulin production in pancreatic b cells in vivo, and to extend the analysis to circulating insulin plasma levels, transgenic mice (HuD Tg) were used in which HuD was transcribed from the CamKII promoter and hence was overexpressed in pancreatic b cells (as well as brain [Bolognani et al., 2006] , Figure S4B ). Compared with the pancreatic b cells of wild-type mice (HuD WT; Figure 4F ), pancreatic b cells of HuD Tg mice expressed higher levels of the myc-tagged HuD transgene and correspondingly lower insulin levels, as assessed by immunofluorescence in islets and by western blot analysis ( Figures 4G and 4H) . The response to changing circulating glucose levels was then assessed in HuD WT and HuD Tg mice by using the intraperitoneal glucose tolerance test (IPGTT). Importantly, HuD Tg mice displayed impaired glucose clearance from blood, as shown by the markedly higher levels of plasma glucose following the glucose challenge (Figure 4I, top) ; at the same time, plasma insulin levels in HuD Tg mice were lower throughout the IPGTT period ( Figure 4I , bottom). These results reveal that HuD Tg mice had less readily releasable insulin in b cells compared with HuD WT mice, which contributed to defective glucose homeostasis. Taken together, our data indicate that HuD represses insulin production in b cells in vivo and thereby contributes to maintaining homeostatic levels of plasma insulin.
DISCUSSION
We report that HuD, previously considered a neuronal protein (Hinman and Lou, 2008) , is also present in mammalian pancreatic b cells, where it regulates insulin levels through the Ins2 5 0 UTR. By interacting with the p27 5 0 UTR, a $400 nt long, highly structured, IRES-containing RNA, HuD repressed p27 translation, likely by disrupting the IRES (Kullmann et al., 2002) . In contrast, the 5 0 UTR of mouse Ins2 mRNA is short (73 nt) as is the 5 0 UTR of human INS mRNA (59 nt), suggesting that HuD does not repress insulin translation by blocking IRES activity. It is also plausible that simply by occupying the Ins2 5 0 UTR HuD blocks translation initiation.
The release of Ins2 mRNA from HuD upon treatment with glucose is reminiscent of the release of HuR-associated mRNAs upon exposure to stress (Abdelmohsen et al., 2007) . Only protein kinase C (PKC) was reported to phosphorylate HuD (Pascale et al., 2005) , but neither the specific phosphorylation site of HuD nor its influence on binding to target mRNAs is known. It will be important to elucidate whether PKC or other kinases are responsible for releasing HuD-bound mRNAs and mobilizing HuD to SGs and PBs following glucose challenge.
It is interesting that basal HuD expression is positively regulated by IR signaling, whereas Ins2 mRNA is rapidly released from HuD after acute exposure to glucose ( Figure 3A) , enabling translation of Ins2 mRNA. The distinct mechanisms of HuD and insulin regulation underscore the complexity of posttranscriptional processes, where RBP levels, binding to target mRNA, and localization are governed separately. These multiple events are likely necessary to respond with appropriate kinetics and magnitude of stimulation. Accordingly ( Figure 4J ), we propose that positive regulation (green arrows) triggered by glucose or insulin can facilitate insulin production post-transcriptionally in an acute time frame (minutes) by releasing HuD from Ins2 mRNA and/or relocalizing HuD. The same trigger can balance these effects via the negative regulation of insulin biosynthesis by enhancing HuD levels transcriptionally (red arrows). The coordination of these positive and negative influences helps to restore insulin to homeostatic levels ( Figure 4J ).
The findings that HuDÀ/À mice express higher insulin while HuD Tg mice express lower insulin (Figure 4 ) support the notion that HuD regulates insulin production in vivo. In light of this result, it will be important to test if HuD function is aberrant in patients with type 2 diabetes. The constitutive levels of HuD, its subcellular distribution, the release of HuD from the INS mRNA in response to glucose or insulin stimulation, all of these parameters warrant study in diabetic and nondiabetic patient populations. For example, in type 2 diabetes, insulin secretion from b cells is severely defective in response to rising circulating glucose, especially in the first 10 min after a glucose load, and therefore it will be important to test if HuD release from INS mRNA is also slow.
Finally, it is worth noting that the microRNA miR-375 represses HuD production by lowering both the levels and translation rates of HuD mRNA (Abdelmohsen et al., 2010) . Interestingly, miR-375 regulates insulin secretion in pancreatic b cells, and miR-375 knockout (375KO) mice have a significantly reduced pancreatic b cell mass compared with WT mice (Poy et al., 2009 ). The authors propose that the hyperglycemia of 375KO mice is largely due to the relative larger a cell compartment (which secretes glucagon) in 375KO mice. However, in 375KO mice, b cells may have higher HuD levels, which lowers insulin production, 
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EXPERIMENTAL PROCEDURES
Cell Culture, Transfection, and Treatment bIRWT and bIRKO cells (Kulkarni et al., 1999; Assmann et al., 2009; Kim et al., 2011) and mouse insulinoma bTC6 cells were cultured in high-glucose DMEM (Invitrogen) supplemented with 10% FBS. Cells were cultured for 16 hr in lowglucose (2 mM) DMEM before stimulation with the indicated glucose concentrations and in low glucose with 0.1% FBS before stimulation with insulin for 24 hr. Chemicals and transfection of siRNA and plasmids are described in Supplemental Information.
Analysis of RNPs (RIP and Biotin Pull-Down) and Chromatin (ChIP) Immunoprecipitation (IP) of endogenous RNP complexes from whole-cell extracts and biotin pull-down analysis were performed as described (supplemental text) using anti-HuD or control IgG antibodies (Santa Cruz Biotechnology). The RNA isolated from IP was further assessed by quantitative real-time PCR (RT-qPCR) analysis. Chromatin immunoprecipitation (ChIP) from bTC6 cells was performed using the EZ-ChIP chromatin IP kit (Millipore, Billerica, MA) following the manufacturer's protocol, using anti-FoxO1 antibody (Abcam) and HuD promoter-specific primers (SA Bioscience). Further description is provided in Supplemental Information.
Animals
Pancreatic sections of normal (wild-type) C57BL/6J mice were used for detection of insulin, HuD, and glucagon. HuDÀ/À, HuD+/À and HuDÀ/À mice (Akamatsu et al., 2005) were used at 14 weeks of age. HuD Tg mice were described (Bolognani et al., 2006) . Mice were anesthetized and tissues were quickly excised and frozen in liquid nitrogen for western blot analysis and ELISA, or fixed in 4% paraformaldehyde for immunostaining. For IPGTT, glucose (1 g/kg body weight) was given intraperitoneally to fasted, 3-month-old female mice for measurement of blood glucose and plasma insulin levels at the indicated times (details in Supplemental Information). All animal protocols were approved by the Gerontology Research Center animal care and use committee of the National Institute on Aging, National Institutes of Health.
Statistics
Quantitative data are presented as the mean ± SEM and compared statistically by Student's t test, using Graphpad Prism (GraphPad Software). A p value of < 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experimental Procedures and can be found with this article online at doi:10.1016/ j.molcel.2012.01.016.
